Join us for this audio version of last week's zoom webinar on rescheduling, a deep dive into the intricate world of drug scheduling and addiction with our esteemed guests: Kevin Sabet, President and CEO of SAM, CADCA policy consultant Sue Thau, and Dr. Russ Kamer. We kick things off by breaking down the history and impact of the 1970 Controlled Substances Act, using relatable analogies to dispel common misconceptions about drug classification. This sets the stage for a compelling discussion on public perception, medical use, and the complexities of drug policy reform.
Get ready for an eye-opening analysis of President Biden's efforts to reschedule marijuana. Starting with a review by the Department of Health and Human Services in October 2022, the process reached an unexpected climax in August 2023. We dissect the irregularities of potentially moving marijuana to Schedule 3 and consider the implications for tax obligations, FDA oversight, and research opportunities. Our panelists bring their unique perspectives to unravel the complexities and uncertainties surrounding this significant policy shift.
Public safety and health implications of rising marijuana use are our final focus. Learn how marijuana's prevalence compares to alcohol and why it's crucial to address misconceptions about its safety. We delve into the challenges of measuring marijuana impairment and emphasize the urgent need for reliable testing methods. With insights from Kevin Sabet, Sue Thau, and Dr. Russ Kamer, we encourage you to engage thoughtfully in the regulatory process and consider the broader implications of these monumental changes in drug policy. Tune in and stay informed!
Follow the work of SAM and FDPS below:
https://learnaboutsam.org/
https://gooddrugpolicy.org/
https://thedrugreport.org/
On X:
https://twitter.com/learnaboutsam
https://twitter.com/GoodDrugPolicy
https://twitter.com/KevinSabet
https://twitter.com/LukeNiforatos
On Facebook: https://www.facebook.com/learnaboutsam
